ABSTRACT. We measured the biochemical response for four patients with maple syrup disease to pharmacologic doses of thiamine, and correlated their response to their branched chain a-ketoacid dehydrogenase activity. We observed a linear correlation between the concentrations of each plasma branched-chain amino acid and its corresponding ketoacid analogue. In addition, the renal tubular reabsorption of branched-chain amino and ketoacids was nearly complete within these physiologic concentrations. Three children responded to thiamine therapy with a reduction in concentration of plasma and urinary branched-chain amino and ketoacids. Each responder had at least 5% activity for branched chain a-ketoacid dehydrogenase in their mononuclear blood cells and in whole cell fibroblasts from cultured skin when compared to the activity in normal control cells. We propose that each child with maple syrup urine disease be assessed for their response to thiamine by quantifying the concentration of branched-chain amino acids in plasma before and after vitamin supplementation. While taking 150 mg/day of thiamine, the brothers decreased their urinary excretion of BCKA and had increased activity of BCKAD as measured in peripheral blood lymphocytes. Based on these and additional in vivo and in vitro studies, Danner and coworkers (7, 8, 1 1-13) proposed that after its conversion to intracellular thiamine pyrophosphate, binding of this active cofactor to the multienzyme complex induced a conformational change which stabilized normal and mutant enzyme. This conformational change decreased the rate of biologic degradation of the complex and over time, increased overall enzyme activity (7, 8, (11) (12) (13) .
ABSTRACT. We measured the biochemical response for four patients with maple syrup disease to pharmacologic doses of thiamine, and correlated their response to their branched chain a-ketoacid dehydrogenase activity. We observed a linear correlation between the concentrations of each plasma branched-chain amino acid and its corresponding ketoacid analogue. In addition, the renal tubular reabsorption of branched-chain amino and ketoacids was nearly complete within these physiologic concentrations. Three children responded to thiamine therapy with a reduction in concentration of plasma and urinary branched-chain amino and ketoacids. Each responder had at least 5% activity for branched chain a-ketoacid dehydrogenase in their mononuclear blood cells and in whole cell fibroblasts from cultured skin when compared to the activity in normal control cells. We propose that each child with maple syrup urine disease be assessed for their response to thiamine by quantifying the concentration of branched-chain amino acids in plasma before and after vitamin supplementation. forms of MSUD (6) (7) (8) (9) (10) . Elsas et al. (8) described the responses of two brothers with MSUD to increasing oral doses ofthiamine. While taking 150 mg/day of thiamine, the brothers decreased their urinary excretion of BCKA and had increased activity of BCKAD as measured in peripheral blood lymphocytes. Based on these and additional in vivo and in vitro studies, Danner and coworkers (7, 8, 1 1-13) proposed that after its conversion to intracellular thiamine pyrophosphate, binding of this active cofactor to the multienzyme complex induced a conformational change which stabilized normal and mutant enzyme. This conformational change decreased the rate of biologic degradation of the complex and over time, increased overall enzyme activity (7, 8, (11) (12) (13) . Because of differences in reported doses and rapidity with which thiamine altered the patient's sensitivity to protein, it has remained unclear which patients would respond and which analysis could predict the response to thiamine therapy. The present study controlled for several variables, including the dietary intake of BCAA and the dose of thiamine. Plasma concentrations and renal transport of BCAA and BCKA were compared in four children affected with MSUD to determine whether pharmacologic doses of thiamine affect renal clearance of BCAA and BCKA. Each patient's biochemical response was correlated with residual activity of BCKAD in freshly isolated blood mononuclear cells and in their cultured skin fibroblasts.
METHODS

--
KIC, a-ketois~ca~roic acid
Clinical protocol. Four patients (Table I) , whose parents gave KMV, a-keto-p-methylvaleric acid their informed consent, were studied. KIV, a-ketoisovaleric acid J.P., a 17-month-old black male, was diagnosed at 13 days of age. His developmental landmarks were moderately delayed.
T.Mc., a 24/~2-yr-old white female, was diagnosed at 19 days of age. Despite normal development, she had recurrent bouts of More than 25 yr ago, Menkes et al. (I) described four siblings otitis, seizures, and ataxia.
with progressive neurologic disorders and sugary-smelling urine.
C.M., a 3'/12-yr-old white female, was treated from 14 days of The fragrant urinary compounds have since been identified as age. She had previous episodes of ketoacidosis and seizures. Her BCKA which accumulated as the result of impairment in the development was moderately delayed. mitochondria1 enzyme complex, BCKAD (E.C. 1.2.4.1.). All V.H., a 9'/2-yr-old-white male was diagnosed at 2 yr. His three BCKA accumulated: KIC; KVM; and KIV (2, 3) . In development was delayed, but he never developed ketoacidosis. patients with MSUD, BCKA results from this impaired catabolic He was the only child in this study whose diet was restricted in pathway. By restricting dietary BCAA early in infancy, the protein without specific restriction of the BCAA. He had taken clinical manifestations of MSUD can be ameliorated or pre-thiamine (100 mg/day) for 7 yr before discontinuing one month vented (4, 5) .
prior to this study. Several patients have been reported with thiamine responsive Before and during the study patients were fed a diet restricted in BCAA determined as optimal by the refemng metabolic of amino acids and organic acids. Mononuclear cells were iso- t Plasma aminoacid concentration was significantly less during thiamine therapy with p < 0.05 using a one-tailed t test for independent mean probability. t Plasma amino acid concentration was significantly less during thiamine therapy with p < 0.05 using a one-tailed t tested for independent mean probability.
lated from heparinized blood for enzyme assays. After baseline studies were completed, the children were given thiamine orally to continue daily at home with their usual diet for 3 wk. During the 4th wk, while continuing thiamine, they were readmitted for fibroblast culture. Quantitation of amino acids, organic acids, and renal tubular transport. Concentrations of amino acids were determined on protein-free filtrates of urine or plasma using lithium buffers in a Beckman 119 CL amino acid analyzer. Organic acids were quantified using gas chromatography of their 0-trimethylsilyl quinoxalinols (14) . Urinary BCKA were determined by gas chromatography of either their methylesters using benzoic acid and [1-'4C] pyruvate as an internal standard and recovery equivalent, respectively (l5), or from their silylated oximes (14) .
Renal filtration, excretion, and reabsorption of BCAA and BCKA were calculated according to the formula (16):
where F = filtered load in pmo1/24 h, GFR = creatinine clearance m1/24 h, P = plasma concentration in pmol/ml, E = urinary excretion in pmo1/24 h, U = urinary concentration in pmol/ml, V = urinary rate in m1/24 h, T = net tubular reabsorption in pmo1/24 h, and %T = percent reabsorption.
Isolation of mononuclear white cells and culture of skin Jibroblast. Granulocyte-free, mononuclear, white blood cells were prepared from 10 ml of heparinized blood using LSM solution (Litton Bionetics, Inc., Kensington, MD), a commercially ob-tained density gradient according to a modification of a previously described method (7, 8) . BCKAD activity from the mononuclear cell fraction of each patient was compared with activity in cells from two controls.
Skin biopsies were obtained and cultured from explants in 75 cm2 plastic tissue culture flasks using Dulbecco-Vogt medium supplemented with 15% fetal bovine serum and 4 mM glutamine. Cells from control and MSUD patients were matched for culture age. Monolayer cultures were harvested by treatment with 0.27% trypsin for 30 min at 37" C.
Enzyme assays. Decarboxylation of 11-I4C] labeled BCAA by mononuclear cells from peripheral blood and by intact cultured fibroblasts was performed using previously described methods (3). Mitochondria1 inner membranes were isolated from fibroblasts (0.75 to 1.5 g wet weight) using Protease VI, homogenization, and differential centrifugation. Mitochondrial pellets were further treated with 0.5 pg digitonin per ng mitochondria1 protein and the inner membrane and matrix were isolated (7, 17) . Branched-chain [ 1 -I4C] a-ketoacids were prepared as previously described (15) . Enzyme activity was monitored by I4CO2 released. The relationship between plasma concentrations of leucine and KIC from all patients is illustrated in Figure 1 . This relationship remained linear over these moderately elevated plasma values. The slope of their least square ratio is approximately one. Thus for any plasma leucine concentration less than 1.0 mM a corresponding KIC concentration was found. The slopes of the least square ratios for KIV to valine and KMV to isoleucine were 0.25 and 0.7, respectively.
Urinary excretion and renal transport of BCAA and BCKA. The urinary excretion of BCAA and BCKA for 72 h under basal conditions and for 72 h during thiamine therapy are shown in Tables 4 and 5. J.P. excreted 39.3% less total BCAA and 56.1% less total BCKA during thiamine therapy. T.Mc. excreted 63.3% less BCAA and 91.7% less BCKA after taking thiamine. C.M. increased excretion of total BCAA by 24.4% but had essentially no change in total BCKA excretion during treatment with thiamine. Her increased excretion of BCAA reflected her elevated plasma concentrations of BCAA during her experimental period. Although V.H. excreted 43.3% more BCAA, his excretion of BCKA decreased by 19.8 % during thiamine therapy.
The renal tubular transport of BCAA and BCKA was calculated before and during thiamine therapy. The rate of filtration for both amino and ketoacids were generally higher before thiamine and reflected the elevated plasma concentrations. However, the maximum tubular reabsorption capacities were not exceeded and more than 99% of all filtered BCAA and BCKA were reabsorbed during both study periods (Tables 6 and 7) .
In vitro BCKAD activity. The ability of freshly isolated mononuclear cells obtained before thiamine therapy to decarboxylate [l-I4C] labeled leucine (20 pM) is shown in Table 8 . Compared with control cells, those of J.P., T.Mc., and V.H. showed, respectively, 5.0,4.9, and 15.7% activity. C.M..'s mononuclear cells had 0.8% of control activity.
BCKAD activity was assayed in whole cell and mitochondrial preparations obtained from cultured skin fibroblasts (Table 8 ). t Urinary concentration of amino acid was significantly less during thiamine therapy with p < 0.05 using a one-tailed test t test for independent mean probability. t Urinary concentration of a-ketoacid was significantly less during thiamine therapy with p < 0.05 using a one-tailed t test for independent mean probability. filtration and excretion were derived from the mean plasma and urinary concentrations of BCAA from two or three collections during each study period. Calculations are described in "Results." Except for V.H. there was close agreement between the enzyme activity in freshly prepared mononuclear cells and fibrobasts grown in vitro.
-h urinarv excretion of the BCAA
DISCUSSION
Since responsivity to thiamine may not correlate with the clinical course, we sought to determine how to predict which patients with MSUD would respond to thiamine therapy. Three of four children in this study responded after 4 wk of thiamine, as demonstrated by improved biochemical status.
Three of these four patients were classified as having classical disease because of their presentation in infancy and recurrent episodes of ketoacidosis (18) . Two of these children, J.P. and T.Mc., had a significant decrease in their fasting plasma concentrations and their 24 h urinary excretion of total BCAA and BCKA during thiamine treatment. V.H. who was classified as having an intermediate form, i.e. developmental delay without bouts of symptomatic ketoacidosis, also had a biochemical response to thiamine. His response might have been blunted as he probably had residual effects of his previous 7 yr of thiamine treatment.
Each patient's response to thiamine correlated with the enzyme activity in their peripheral blood monocytes. The three patients with residual enzyme activity of approximately 5% or more, showed an in vivo response to thiamine. C.M. with less than 1 % activity in her white cells, did not respond. She subsequently died during an episode of severe ketoacidosis.
The higher enzyme activity in V.H.'s freshly isolated peripheral blood mononuclear cells as compared to that in his skin fibro- blasts may have also reflected his previous thiamine therapy. Unlike the mononuclear cell and whole cell fibroblast assay, the mitochondria1 assays required addition of all soluble cofactors and contained saturating amounts of thiamine pyrophosphate. This assay may more accurately define the maximal activity of normal and mutant enzymes, but does not define the functional activity in the intact cell.
While we, as have others (19) , found a linear correlation between plasma concentrations of each BCAA and its ketoacid analogue, an unexpected finding was the efficient renal tubular reabsorption of BCAA and BCKA within these physiologic conditions. Reflecting elevated plasma concentrations, the rates of filtration of BCAA and BCKA were higher before thiamine therapy. However, all BCAA and BCKA were maximally reabsorbed in all children during both study periods. Thus the reduced plasma concentrations of BCAA and BCKA in three responders did not result from increased urinary excretion. These observations differ from Lancaster, et al. (20) who found a higher ratio of BCKA to BCAA in the urine compared to that in the blood, and concluded that the BCKA were preferentially excreted by urinary tubular secretion. There are at least two possible explanations for these different observations. Lancaster et a/. (20) made their observations in one newborn female. Her serum concentrations of BCKA were five to 10 times greater than in our patients. Additionally, renal transport of amino acids in older children is more efficient than in a newborn infant (2 1). If both BCAA and BCKA are maximally reabsorbed, an additional treatment of the acute ketoacidosis of MSUD would be to ~ -~ -enhance excretion of BCKA. Several mechanisms could explain thiamine responsivity. We proposed one such model (7, 8, 1 1, 12) . By increasing thiamine intake, intracellular concentrations of thiamine pyrophosphate increase and saturate binding sites on the decarboxylase moiety of the BCKAD complex. The complex undergoes a conformational change, rendering it more resistant to biologic degradation and thus increasing its-total activity by prolon&g its biologic half-life. Assuming that patients with MSUD have normal mechanisms for absorption of thiamine, and conversion to thiamine pyrophosphate, the differences in clinical responsivity reflect the ability of thiamine pyrophosphate to bind and stabilize the mutant complex. Chuang et al. (22) have proposed an alternate model by finding a thiamine pyrophosphate mediated increase in affinity of BCKAD for the BCKA in cells cultured from a patient originally described by Scriver et al. (6) . The data from this current study are compatible with either model. If thiamine pyrophosphate saturation produced stabilization or increased affinity of a mutant enzyme complex to BCKA then those mutations with at least a critical amount of residual activity would most likely respond with an increase in the level of enzyme activity. Such a response to excess thiamine would not be expected if there were * FERNHOFF ET AL. a major conformational change in the protein, or if the protein were absent because of a regulatory mutation. Further explanations for vitamin responsivity await in vitro confirmation by complementation studies of various cell lines with mutant BCKAD, and better resolution at the molecular level.
With increased newborn screening for MSUD and other metabolic disorders we must define clinical and biochemical criteria for responsivity to dietary and vitamin therapies. Control studies are rarely performed on the newly diagnosed neonate. Therefore, experiences gained from the study of older children must be used in the neonate. Based on our experiences with these and other patients, we believe that after the diagnosis of MSUD has been established, all infants should be started on thiamine (10 to 20 mg/kg/day) and a diet restricted in BCAA. A biochemical response to thiamine may require 3 to 4 wk.
